PerkinElmer to buy SIRION Biotech

PerkinElmer Inc. (PKI) agreed to buy SIRION Biotech GmbH, a provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

Headquartered in Munich, Germany, privately held SIRION has about 50 employees based in Germany, the U.S. and France.

The deal will complement PerkinElmer's Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bio production and base editing technologies, PerkinElmer said in a statement.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PerkinElmer. (2021, June 24). PerkinElmer to buy SIRION Biotech. News-Medical. Retrieved on March 29, 2023 from

  • MLA

    PerkinElmer. "PerkinElmer to buy SIRION Biotech". News-Medical. 29 March 2023. <>.

  • Chicago

    PerkinElmer. "PerkinElmer to buy SIRION Biotech". News-Medical. (accessed March 29, 2023).

  • Harvard

    PerkinElmer. 2021. PerkinElmer to buy SIRION Biotech. News-Medical, viewed 29 March 2023,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
PerkinElmer unveils industry-first cell analysis solution to streamline cell and gene therapy research and manufacturing